IL-5 R alpha Overview
Molecule Name
Interleukin-5 receptor subunit alpha
Synonyms
IL5Ra,CD125
Drug Development Progress
Drugs in Clinical Trials2
Approved Drugs1
Highest Development StageApproved
Target Synonym
Interleukin 5 Receptor， Alpha，Interleukin-5 Receptor Subunit Alpha，HSIL5R3，Interleukin-5 Receptor Alpha Chain，CDw125，Interleukin-5 Receptor alpha Subunit，Interleukin 5 Receptor Type 3，CD125 Antigen，Interleukin 5 Receptor Subunit Alpha，IL-5 Receptor Subunit Alpha，IL-5R-Alpha，IL5R，IL5RA，CD125，IL-5RA，IL-5R Subunit Alpha
Background
Interleukin-5 receptor subunit alpha (IL5RA) is also known as IL-5 receptor subunit alpha, IL-5R subunit alpha and CD125,which is a single-pass type I membrane protein that belongs to the type I cytokine receptor family and type 5 subfamily.IL5R, a heterodimer of an alpha and a beta subunit, is expressed on eosinophils and basophils. IL5RA / CD125 is the receptor for interleukin-5 (IL5) and the alpha chain can bind to IL5. The WSXWS motif of IL5RA appears to be necessary for proper protein folding and thereby efficient intracellular transport and cell-surface receptor binding.The beta subunit of IL5R is common to the IL3, IL5 and GM-CSF receptors.
IL-5 R alpha Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| IL-5 CAR-T Cell Therapy (Zhejiang University) | Phase 1 Clinical | Zhejiang University | Hematologic Diseases; Neoplasms | Details | |
| Trabikibart | CSL-311 | Phase 1 Clinical | Csl Ltd | Asthma | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Benralizumab | KHK-4563; MEDI-563; BIW-8405; BIW-8405-IL-5R | Approved | Biowa Inc, Medimmune Llc | Fasenra, 凡舒卓 | United States | Asthma | Astrazeneca Ab | 2017-11-14 | Asthma; Asthma, Exercise-Induced; Bronchiectasis; Chronic Urticaria; Dermatitis; Dermatitis, Atopic; Drug Hypersensitivity Syndrome; Eczema; Eosinophilia; Eosinophilic Asthma; Eosinophilic Esophagitis; Eosinophilic gastroenteritis (EG); Eosinophilic Granulomatosis With Polyangiitis; Gastroenteritis; Genetic Diseases, Inborn; Granulomatosis with Polyangiitis; Hematologic Diseases; Hypereosinophilic Syndrome; Hypersensitivity; Hypersensitivity, Immediate; Immune System Diseases; Leukocyte Disorders; Nasal Polyps; Pemphigoid, Bullous; Pulmonary Disease, Chronic Obstructive; Respiratory Tract Diseases; Sinusitis; Skin Diseases; Skin Diseases, Eczematous; Skin Diseases, Genetic | Details |